- New Product Targets $2.12 Billion Specialized and Growing U.S. Nutritional Supplement Market for 'Immunostimulants' - Exclusive Agreement Results in Carrington's Manapol(R) Being Combined With MaitakeGold 404(R) for Unique Immune System Enhancer
IRVING, Texas, Nov. 20 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Nasdaq: CARN) today announced that its subsidiary Caraloe, Inc. has obtained the exclusive right among manufacturers of products from the Aloe vera L. plant to use MaitakeGold 404(R) in combination with any product produced from aloe. The arrangement is with the Tradeworks Group, Inc. of Brattleboro, Vermont, which holds the North American marketing and distribution rights to the Maitake Beta-[1,6]- and [1,3]-Glucans extract found in maitake mushrooms and protected by U.S. patent 5,854,404.
Manapol(R) is a proprietary raw material from Aloe vera L. naturally containing Beta-[1,3]-Glucans. Caraloe, under the AloeCeuticals(R) label, markets a regular Manapol(R) immune system stimulant plus a Manapol(R) enriched with beta glucans. Caraloe will now market its third product in the immune system stimulant line with Manapol(R) plus MaitakeGold 404(R). Both Manapol(R) and MaitakeGold 404(R) have been used in oral preparation for several years with no reported health issues.
The product targets the growing nutritional supplements market, which is estimated by "Nutrition Business Journal" to be about $17 billion in the U.S. Of that, the specialized market for immune enhancing products is about $2.12 billion and is one of the fastest growing categories.
Suzanne McNeary, Tradeworks' vice president of marketing, in the July/August 2002 issue of "Nutraceutical World Magazine," stated, "Natural product surveys are indicating that the immuno-stimulant category is one of the fastest growing areas for dietary supplements because health conscious consumers are using these types of products to fend off a variety of conditions." She added, "In addition, several researchers, health practitioners and patients are turning to alternative medicines to aid in immunology against more serious health conditions."
Unique Immune System Enhancer
"MaitakeGold 404(R), scientifically extracted from the maitake mushroom, is one of the more comprehensive immunostimulants available in the dietary supplement category and has been substantiated for several DSHEA (Dietary Supplement Health and Education Act of 1994) structure/function claims for immune support," said Walt Jones, president of Caraloe. "Likewise, our Manapol(R) material, also a combination of naturally occurring substances, carries a DSHEA claim that it promotes and enhances immune system activity. The combination of the two offers a unique immune enhancement product."
Jones added, "Manapol(R) is a patent protected 'product by process' and is to my knowledge the only refined product available from the Aloe vera L. plant that carries a DSHEA claim. Additionally, it is the only product from Aloe vera where the consumer knows exactly how many milligrams are available in each capsule, tablet, powder or drink formulation. Moreover, Manapol(R) is produced in an ISO-certified facility under cGMPs for human oral drug production and is produced from certified organically grown aloe."
Manapol(R) is a registered trademark of Carrington Laboratories recognized worldwide. Manapol(R) products are distributed domestically and internationally and have a recognized and growing presence in Japan, Taiwan and other Pacific Rim countries.
Taken on an ongoing basis, MaitakeGold 404(R), known in Japan as Maitake MD-Fraction, may play a significant protective role by supporting the body's immune system activity. MaitakeGold 404(R) is a highly concentrated maitake mushroom-derived beta glucan extract that helps support health by promoting cellular immune response and therefore cellular health. Additionally, MaitakeGold 404(R) may provide healthy immune response support to individuals challenged by environmental and lifestyle stressors.
About Manapol(R) Powder
Because of its unique and patented composition of matter, Manapol(R) Powder stimulates very specific white blood cells called macrophages. Macrophages are cells that patrol throughout the body and seek out, meet, and address challenges to the immune system. In this way macrophages are able to "up-regulate" and enhance immune system response. Manapol(R) comes in 150 mg tablets, 40 mg capsules, 160 mg powder and 40 mg/oz in liquid formulations. Each milligram of regular Manapol(R) Powder contains one microgram of naturally occurring beta glucans.
About Tradeworks Group
Tradeworks Group is a diversified nutraceutical product marketing company dedicated to the development and commercialization of proprietary, scientifically researched ingredients for human and animal nutrition. Tradeworks merges advanced nutritional technology with exceptional marketing skills to create novel nutraceutical ingredients designed to excel in the dietary supplement and functional foods marketplace. Additional information about Tradeworks is available at its home page at http://www.tradeworksgroup.com .
Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care; manufacture and market the nutraceutical raw materials Manapol(R) and Hydrapol(TM); and market consumer products under the AloeCeuticals(R) brand. Carrington's technology is protected by more than 120 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by both companies' management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; supply of Manapol(R) or MaitakeGold 404(R); changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10Q filed November 14, 2002.